{"id":640,"date":"2026-08-23T15:56:31","date_gmt":"2026-08-23T15:56:31","guid":{"rendered":"https:\/\/syrian-biomedica.com\/?page_id=640"},"modified":"2026-08-23T21:34:09","modified_gmt":"2026-08-23T21:34:09","slug":"charles-malek-abstract-2","status":"publish","type":"page","link":"https:\/\/syrian-biomedica.com\/ar\/charles-malek-abstract-2\/","title":{"rendered":"Charles Malek Abstract"},"content":{"rendered":"<h1><strong>Charles Malek<\/strong><\/h1>\n<div>\n<p><strong>From Bench to Biotechnology: PI3KC2\u03b2 as a Vascular-Protective Target in Acute Ischemic Stroke<\/strong><\/p>\n<\/div>\n<div>\n<p>Acute ischemic stroke remains a major cause of mortality and long-term disability worldwide. Although reperfusion therapies have substantially improved clinical outcomes, restoration of cerebral blood flow can also contribute to endothelial dysfunction, blood\u2013brain barrier disruption, cerebral edema, and secondary tissue injury. Preservation of vascular integrity during ischemia and reperfusion therefore represents an important therapeutic opportunity.<\/p>\n<\/p>\n<p>Recent experimental studies have identified the class II phosphoinositide 3-kinase PI3KC2\u03b2 as a regulator of endothelial barrier integrity. Genetic inactivation of PI3KC2\u03b2 has been shown to enhance VE-cadherin trafficking and stabilization at endothelial cell-cell junctions and to protect vascular integrity in experimental models of ischemia-reperfusion injury, providing a rationale for investigating PI3KC2\u03b2 as a potential therapeutic target in acute ischemic stroke.<\/p>\n<\/p>\n<p>However, the identification of a promising biological target represents only the first step toward therapeutic translation. Moving from an academic discovery toward a potential medicine requires coordinated progress across target validation, drug discovery, intellectual property, preclinical development, regulatory strategy, financing, and the establishment of multidisciplinary scientific and clinical partnerships.<\/p>\n<\/p>\n<p>Using PI3KC2\u03b2 and acute ischemic stroke as a translational case study, this presentation will discuss the pathway from fundamental biological discovery to therapeutic development and biotechnology entrepreneurship. Particular emphasis will be placed on the practical and strategic decisions required to move a project beyond the academic laboratory, including building a complementary founding team, establishing academic and industrial partnerships, protecting intellectual property, identifying financing opportunities, and creating a biotechnology company around an emerging therapeutic concept.<\/p>\n<\/p>\n<p>The presentation aims to illustrate how mechanistic scientific discoveries can be translated into clinically oriented innovation and how researchers can actively contribute to the progression of discoveries from bench to biotechnology development.<\/p>\n<\/div>\n<p><!--more--><br \/>\n<!-- {\"type\":\"layout\",\"children\":[{\"name\":\"Terms\",\"type\":\"section\",\"props\":{\"image_position\":\"center-center\",\"style\":\"default\",\"title_breakpoint\":\"xl\",\"title_position\":\"top-left\",\"title_rotation\":\"left\",\"vertical_align\":\"\",\"width\":\"small\"},\"children\":[{\"type\":\"row\",\"children\":[{\"type\":\"column\",\"props\":{\"image_position\":\"center-center\",\"position_sticky_breakpoint\":\"m\",\"width_medium\":\"1-1\"},\"children\":[{\"type\":\"headline\",\"props\":{\"content\":\"<strong>Charles Malek<\\\/strong>\",\"image_align\":\"left\",\"image_margin\":\"xsmall\",\"margin_top\":\"remove\",\"title_element\":\"h1\",\"title_style\":\"heading-medium\"}},{\"type\":\"headline\",\"props\":{\"content\":\"\n\n<p><strong>From Bench to Biotechnology: PI3KC2\\u03b2 as a Vascular-Protective Target in Acute Ischemic Stroke<\\\/strong><\\\/p>\",\"image_align\":\"left\",\"image_margin\":\"xsmall\",\"margin_bottom\":\"remove\",\"title_color\":\"muted\",\"title_element\":\"div\",\"title_style\":\"h4\"}},{\"type\":\"text\",\"props\":{\"column_breakpoint\":\"m\",\"content\":\"\n\n<p>Acute ischemic stroke remains a major cause of mortality and long-term disability worldwide. Although reperfusion therapies have substantially improved clinical outcomes, restoration of cerebral blood flow can also contribute to endothelial dysfunction, blood\\u2013brain barrier disruption, cerebral edema, and secondary tissue injury. Preservation of vascular integrity during ischemia and reperfusion therefore represents an important therapeutic opportunity.<\\\/p>\\n\n\n<p><\\\/p>\\n\n\n<p>Recent experimental studies have identified the class II phosphoinositide 3-kinase PI3KC2\\u03b2 as a regulator of endothelial barrier integrity. Genetic inactivation of PI3KC2\\u03b2 has been shown to enhance VE-cadherin trafficking and stabilization at endothelial cell-cell junctions and to protect vascular integrity in experimental models of ischemia-reperfusion injury, providing a rationale for investigating PI3KC2\\u03b2 as a potential therapeutic target in acute ischemic stroke.<\\\/p>\\n\n\n<p><\\\/p>\\n\n\n<p>However, the identification of a promising biological target represents only the first step toward therapeutic translation. Moving from an academic discovery toward a potential medicine requires coordinated progress across target validation, drug discovery, intellectual property, preclinical development, regulatory strategy, financing, and the establishment of multidisciplinary scientific and clinical partnerships.<\\\/p>\\n\n\n<p><\\\/p>\\n\n\n<p>Using PI3KC2\\u03b2 and acute ischemic stroke as a translational case study, this presentation will discuss the pathway from fundamental biological discovery to therapeutic development and biotechnology entrepreneurship. Particular emphasis will be placed on the practical and strategic decisions required to move a project beyond the academic laboratory, including building a complementary founding team, establishing academic and industrial partnerships, protecting intellectual property, identifying financing opportunities, and creating a biotechnology company around an emerging therapeutic concept.<\\\/p>\\n\n\n<p><\\\/p>\\n\n\n<p>The presentation aims to illustrate how mechanistic scientific discoveries can be translated into clinically oriented innovation and how researchers can actively contribute to the progression of discoveries from bench to biotechnology development.<\\\/p>\",\"margin\":\"default\"}}]}]}]}],\"version\":\"4.5.32\"} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Charles Malek From Bench to Biotechnology: PI3KC2\u03b2 as a Vascular-Protective Target in Acute Ischemic Stroke Acute ischemic stroke remains a major cause of mortality and long-term disability worldwide. Although reperfusion therapies have substantially improved clinical outcomes, restoration of cerebral blood flow can also contribute to endothelial dysfunction, blood\u2013brain barrier disruption, cerebral edema, and secondary tissue [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":"","_et_pb_custom_css":""},"class_list":["post-640","page","type-page","status-publish","hentry"],"_et_pb_custom_css":"","_links":{"self":[{"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/pages\/640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/comments?post=640"}],"version-history":[{"count":1,"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/pages\/640\/revisions"}],"predecessor-version":[{"id":662,"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/pages\/640\/revisions\/662"}],"wp:attachment":[{"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/media?parent=640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}